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Abstract 
Background: Prostate cancer (PCa) remains to be a diagnostic challenge due to its variable presentation and the 
lack of reliable diagnosis tool. MicroRNAs (miRNAs) regulate gene in extensive range of pathophysiologic processes. 
Plasma miRNAs are ideal biomarkers in heart failure, diabetes and other disease. However, using circulating miRNAs as 
biomarkers for the diagnosis of PCa is still unknown.
Methods: 149 PCa patients, 57 healthy controls, and 121 non-cancer patients (benign prostatic hyperplasia and 
other urinary diseases) were enrolled in this study. The reverse transcription of miRNA and SYBR-Green-based double 
standards curve miRNA quantitative polymerase chain reactions (qPCR) were used to evaluate the dysregulated miR-
410-5p. Receiver operator characteristic (ROC) curve analysis was used to evaluate the diagnostic accuracy of miR-
410-5p identified as the alternative biomarker.
Results: Circulating miRNA-410-5p (miR-410-5p) level was significantly higher in the PCa patients than in healthy 
controls or non-cancer patients. ROC curve analysis showed that plasma miR-410-5p was a specific diagnostic bio-
marker of PCa with an area under curve(AUC) of 0.8097 (95 % confidence interval, 0.7371–0.8823; P < 0.001).
Conclusions: The serum miR-410-5p level is a potential biomarker for the diagnosis of PCa.
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Background
Prostate cancer (PCa) is the development of cancer in the 
prostate associated with a substantial morbidity and mor-
tality [1, 2]. It has reported that 233,000 new cases and 
29,480 deaths occurred in the year 2014 [2, 3]. Early diag-
nosis and treatment before tumor metastasizes is crucial 
for improving the patient survival [1, 4]. The 5 year sur-
vival ratio for men diagnosed while the PCa is localized 
is nearly 100 %. And only 28 % of the men who diagnosed 
with metastatic PCa survive beyond 5 years [5]. There are 
still to be challenges for the early diagnosis of PCa due to 
its variable presentation [6].
Diagnostic testing for PCa has been widely studied and 
searches from biomarkers [7, 8], such as the prostate-
specific antigen (PSA) assay [9], to radiologic imaging, 
such as magnetic resonance imaging (MRI) [8, 10], and 
Biopsy [11]. Although widely used as a diagnosis tool, 
serum PSA assays are sensitive but not specific enough to 
detecting PCa [4, 9, 12]. Novel biomarkers with enhanced 
detective accuracy would greatly assist the diagnosis of 
PCa [13].
Recently, microRNAs (miRNAs) have been found to 
play crucial roles in many cancer cellular processes, 
such as proliferation [14, 15], differentiation [12, 16] and 
apoptosis [2]. MiRNAs are small, endogenous, noncod-
ing RNAs with single-stranded RNA that regulate gene 
expression by combine with messenger RNAs (mRNAs) 
and inhibiting the translation or promoting degradation 
of mRNA [17, 18]. Our research found that miR-410-5p 
were secreted by prostate cancer cells and released into 
peripheral blood. We therefore sought to explore the 
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Methods
The populations of patients
Between February 2010 and July 2011, 327 patients with 
a high probability of PCa or those with an intermediate 
probability and a positive PSA enzymelinked immuno-
sorbent assay test (ELISA) (>4 μg/L) in Shanghai Chang-
hai Hospital were testing to confirm PCa. In accordance 
with the existing clinical guidelines, these patients under-
went a biopsy test for prostate to confirm the prostate 
cancer. After the diagnosis of PCa, Gleason score was 
examined to evaluate the microscopic features of pros-
tate cancer found. Serum PSA was used as a biomarker 
of PCa risks and treatment prognosis. Afterwards, risk 
stratification was evaluated according to the clinical 
guidelines. Briefly, high risk PCa is diagnosed if gleason 
score is higher than 7 [19]. Intermediate-risk PCa is con-
firmed gleason score is 7 and PSA is between 10–20 ug/L. 
Low-risk PCa is confirmed when gleason level is lower 
than 7 [19]. During the period, 187 of 421 patients were 
diagnosed to have PCa, and 149 of the 187 patients which 
gave informed permit were enrolled in this research. The 
controls included 57 healthy volunteers, 81 patients with 
BPH and 40 patients with other urinary diseases. Moreo-
ver, 44 of 85 high-risk PCa patients were treated with sur-
gery and others were treated with radiation therapy and 
chemotherapy. Approval was obtained from the ethical 
management committees of the Second Military Medical 
University. All participants gave written informed permit 
before sampling in the study.
Serum sampling and total RNA isolation
At presentation, peripheral blood samples for miR-
410-5p detection were collected in coagulation-promot-
ing tubes [20] (BD, New York, USA) and processed within 
1 h of collection. After centrifugation (4  °C at 3000g for 
5 min), supernatant was transferred to RNase -free tubes 
and stored at −80 °C.
Total RNA was isolated from serum using a Trizol 
LS isolation kit (Thermo Fisher, Massachusetts, USA) 
according to the manufacturer’s instructions [21]. Briefly, 
300 μL of human serum was used on the total RNA iso-
lation. Each product of isolation was eluted in 50  μL 
of RNAse-free water. RNA quantification of human 
plasma samples was done by Spectrophotometric. The 
absorbance on 230, 260, 280 and 330  nm was detected 
to evaluate the severity of undetermined contaminants 
in isolation products. Thus, all RNA samples were ana-
lyzed for U6 expression, a stable endogenous reference 
non-coding RNA [22], to assess the approximate yield of 
RNA islation and to ensure that proportionate amounts 
of serum were used in each reaction of reverse transcrip-
tion and qPCR.
Quantification of miR‑410‑5p expression
The miRNAs reverse-transcription were performed 
using the Miscript RT kit [23] (#218161,QIAGEN, Ger-
many), and the products were re-package into two 
tubes. QPCR with SYBR Green (#218073 and #218300, 
QIAGEN, Dusseldorf, Germany) were performed on 
RNA from serum samples of 57 randomly selected PCa 
patients and 14 healthy controls. QPCR steps were per-
formed on Rotorgene 6000 Real-Time PCR System 
(Corbett, Sydney, Australia); the results were expressed 
as Ct values and normalized to calculate the average Ct 
of each sample (ΔCt). The relative expression of miR-
410-5p was calculated using comparative Ct method [24] 
(2-ΔΔCt). Amplification of U6 was done with primers: 
5′-CTCGCTTCGGCAGCACA-3′; 5′-AACGCTTCACG 
AATTTGCGT-3′ as internal control [25]. All tests were 
run in triplicate to minimize the experimental error.
Single miRNA expression was determined using SYBR 
Green-based miRNA qRT-PCR (#218073 and #218300, 
QIAGEN, Dusseldorf, Germany) according to the man-
ufacturer’s instructions. The qRT-PCR was performed 
on 327 samples mentioned before. Briefly, the 15 μL RT 
reaction master mix was created with 5 μL of total RNA 
sample which was isolated as described above. Reverse 
transcription and qPCR was carried out using the Rotor-
gene 6000 Real-Time PCR System (Corbett, Sydney, Aus-
tralia) on 20 μL of PCR master mix containing 10 μL of 
SYBR-Green QPCR Master Mix, 1 μL of primer, 1 μL of 
RT products and 8 μL of RNase free water. The qPCR 
reactions were performed in triplicate. Due to the lack 
of generally accepted standards, double standard curve 
was made for endogenous control and quantification. All 
reactions were run in triplicate. QPCR products of miR-
410-5p and U6 was recombined into pMD18T as stand-
ards [26].
For comparison test, qPCR was performed on 73 RNA 
samples from the cohort provided above (Including 34 
randomly selected PCa patients, 25 BPH patients and 14 
healthy controls). The relative expression of miR-410-5p, 
miR-1228 and let-7c was calculated using comparative Ct 
method. Amplification of let-7c was performed as a posi-
tive control according to the following Ref. [27, 28] and 
amplification of miR-1228 was performed as a negative 
control [29].
Statistical analysis of miR‑410‑5p
Data characterized by the normal classification were 
expressed as the average and standard deviation. miR-
410-5p content is widely presented using the double 
standard curve method. Recombinant vector pMD18T-
miR-410-5p and pMD18T-U6 were proliferated, 
extracted with DH5a and accurately quantified as the 
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standards [26]. The Ct values of samples were compared 
with standards to calculate the copy numbers [30]. A Chi 
squared test,independent samples t test or one-way anal-
ysis of variance (ANOVA) was done when appropriate. 
If significant differences were found, a Bonferroni post 
hoc test was done to determine which teams differed 
significantly according to equal variance criterion. After 
that, the receiver-operator characteristic curve (ROC) 
analysis was performed with plasma miR-410-5p distin-
guishing between PCa patients and non-cancer controls 
or different stage PCa patients. The value of area under 
ROC curve (AUC) was estimated to criticize the diagnos-
tic accuracy of miR-410-5p. All analyses were performed 
using Microsoft Excel 2013 by two-sided. For all analyses, 
p values <0.05 were considered statistically significant 
[31].
Results
miR‑410‑5p contents in the plasma of PCa patients
Plasma miR-410-5p were identified as the biomarker in 
57 PCa patients from 14 healthy controls (Fig.  1a). The 
elevation of miR-410-5p was validated using double 
standard curve qRT-PCR in 149 PCa patients and 178 
non-cancer controls (Fig.  1b). The basic clinical char-
acteristics of PCa patients and non-cancer patients 
are shown in the Table  1. It showed that there were no 
remarkable differences in age between the PCa and non-
cancer groups. These data have been normalized by dou-
ble standard curves, a widely used normalized method 
for qPCR that was also confirmed in our other research. 
Moreover, we compared the difference in miR-410-5p 
content between 85 high-intermediate risk PCa patients 
and 64 low-risk PCa patients and obtained the same dif-
ferences in miR-410-5p expression (Fig.  1c), which fur-
ther supports that miR-410-5p is a stable biomarker for 
PCa.
The plasma miR-410-5p level was increased in the 
PCa group compared to both the non-cancer group and 
healthy controls (Fig.  1a). However, plasma miR-410-5p 
was also higher in the serums of PCa patients with-
out recurrence than in the serums of PCa patients with 
poor prognosis (Fig. 2a), indicating that miR-410-5p may 
be a stable biomarker to evaluate the prognosis of PCa. 
To confirm that the assay is reproducible, all tests were 
repeated twice. It must be confirmed that no remark-
able difference in the content of miR-410-5p was found 
between three tests of one sample. We also compared the 
plasma miR-410-5p level between high-intermediate risk 
PCa and low-risk PCa and found that the miR-410-5p 
level was significantly higher in the low-risk patients 
compared to high-intermediate-risk PCa patients 
(Fig. 1c).
It’s also found approximately distinctions between 
PCa patients and healthy controls in plasma miR-410-5p 
levels and let-7c levels (Fig.  2b). Let-7c was known as a 
potential biomarker for PCa diagnosis [27, 28] and was 
used as positive control in this study. QPCR of miR-1228 
was performed as a negative control for its steady expres-
sion in the blood [29].
Diagnostic accuracy of plasma miR‑410‑5p for PCa
The ROC curve analysis was performed to evaluate the 
diagnostic accuracy of serum miR-410-5p. When a com-
parison was made between the PCa group compared to the 
Fig. 1 Serum miR-410-5p levels in different groups. a The relative serum miR-410-5p levels in 20 healthy controls and 51 PCa patients. The value of 
miR-410-5p was provided above the histogram. **, P < 0.01. b The Serum miR-410-5p level in 57 healthy volunteers, 121 non-PCA controls (include 
81 patients with BPH and 40 patients with other urinary diseases) and 149 PCA patients. The value of miR-410-5p was provided above the histo-
gram. **, P < 0.01. c The Serum miR-410 levels in 65 low-risk PCa patients (Gleason level <7) and 84 high-intermediate-risk PCa (Gleason level >=7). 
The value of miR-410-5p was provided above the histogram. **, P < 0.01
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non-cancer control group, the AUC value was 0.8097 (95 % 
confidence interval, 0.7371–0.8823; P  <  0.001) (Fig.  3a). 
When the comparison was made between the high-interme-
diate risk PCa and low-risk PCa group, the AUC value was 
0.7125 (95 % confidence interval, 0.6292–0.7958; P = 0.002). 
Using 21.4  ng/L as a threshold for the serum miR-410-5p 
level, the specificity and sensitivity of plasma miR-410-5p 
for the diagnosis of PCa in patients reporting PSA >4 ng/L 
(Fig.  3b). In addition, co-diagnosis by plasma miR-410-5p 
and PSA distinguished PCa cases from healthy controls plus 
non-PCa cases had an AUC value of 0.8274 (95 % confidence 
interval, 0.7029–0.9519; P < 0.001) (Fig. 3a).
Discussion
PCa has a nonspecific clinical biomarker presentation 
and is hard to diagnose [4, 6]. Although great progress 
has been found in the detection and exclusion of PCa 
with the advent of PSA assay [1], radiologic imaging [10] 
and biopsy [11], there is still a superior need for specific 
and reliable biomarker for the detection early diagnostic 
testing of PCa. In our study, we confirmed serum miR-
410-5p as a potential biomarker for PCa [13]. Ideally, a 
biomarker should be repeatable and have a high specific-
ity and sensitivity for the diagnosis of a pathognomonic 
disease [32]. miRNAs are suitable potential biomarkers 
because of their fulfilling many of these criteria [33–36]. 
Furthermore, miRNAs are present in human periph-
eral blood in a greatly stable form that is protected from 
RNase activity and remain stable even in harsh condi-
tions [17, 24, 37]. The stability, lower structure complex-
ity, and lack of modifications make circulating miRNAs 
to be ideal diagnostic biomarker candidates [38]. The 
high specificity and sensitivity of miRNA detection using 
reverse transcription and qPCR may create accurate cut-
off values for diagnosis. Until now, the function of serum 
miR-410-5p in PCa has not been reported. As confirmed 
by the miR-410-5p in this study, the application of miR-
NAs as minimally stable and sensitive biomarkers would 
result in great breakthroughs for the diagnosis of com-
mon disease [39, 40].
PSA assay and biopsy test is widely used in the clini-
cal PCa diagnosis. The sensitivity of PSA assay alone was 
82.4 %, whereas the combination of PSA assay and biopsy 
test increased the sensitivity to 87.1 % [41]. However, the 
specificity of PSA assay is not enough to make a definite 
diagnosis on PCa, and biopsy is a traumatic test on pros-
tate and cannot improve the quality-adjusted life-year 
(QALY) [42]. Plasma miR-410-5p might be an appropri-
ate alternative. In addition, using plasma miR-410-5p was 
not a traumatic test and the co-diagnosis improves the 
specificity of PSA.
Table 1 Clinical characteristics of  prostate cancer (PCA) 
patients and non-PCA patients
Characteristics PCa (n = 149) Non‑PCa (n = 178)
Age 73.55 ± 7.36 73.25 ± 6.13
PSA 24.62 ± 24.56 1.78 ± 0.88
Risk stratification
 Low risk 57 –
 Intermediate risk 51 –
 High risk 41 –
Recurrence
 Biochemical 35 –
 Metastasis 14 –
Treatments
 Surgery 47 3
 Radiotherapy 27 0
 Hormonotherapy 18 0
Fig. 2 Serum miR-410-5p levels in PCa patients and comparison test with miR-1228 and let-7c. a The relative serum miR-410-5p level in 115 good 
prognosis patient (no recurrence) and 34 PCa patients with poor prognosis. The expression levels of miR-410-5p was normalized by U6. The value of 
miR-410-5p was provided above the histogram. **, P < 0.01. b The relative serum level of let-7c, miR-410-5p, and miR1228 in 73 samples (Including 
34 randomly selected PCa patients, 25 BPH patients and 14 healthy controls). The expression levels were normalized by U6. The value of miRNAs 
level and p value were provided above the histogram
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We have demonstrated that the plasma miR-410-5p 
level was not affected by non-cancer conditions. Plasma 
miR-410-5p could distinguish PCa cases from healthy 
controls or non-cancer cases with an AUC value of 
0.8097 or 0.7652, which indicates that serum miR-410-5p 
could to be a potential biomarker to diagnose PCa. Fur-
thermore, our recent research confirmed that the expres-
sion of miR-410-5p was 7.5-fold higher in the peripheral 
blood dendritic cells (DCs) of PCa patients compared to 
non-cancer controls. In this study, the serum miR-410-5p 
level in 26 patients with chronic prostatitis and 14 with 
an acute urinary tract infection was similar to the healthy 
controls. This result may suggest the function of miR-
410-5p and give an explanation for the expression and 
secrete of miR-410-5p.
Our study was subject to several limitations. First, for 
clinical study, 327 patients (include 149 PCa patients) 
were relatively small in scale. And the results will require 
further replication in independent studies of PCa. Sec-
ond, it would to be necessary to study the function of 
miR-410-5p in both PCa and other-disease patients. 
Third, it would be helpful to research whether combin-
ing the values of serum miR-410-5p content and PSA 
assay would greatly enhance the sensitivity and specific-
ity for plasma miR-410-5p. Further studies are needed to 
resolve this tissue specificity. However, the PSA assay was 
a high-sensitivity and low-specific diagnostic method 
because it is also positive in the patients with prostatitis, 
benign prostatic hyperplasia, and other prostate diseases 
[42]. The specificity of miR-410-5p in diagnosing PCa 
was better than PSA assay in this study. Forth, further 
study is required to determine the additional benefit of 
miR-410-5p in staging and prognostic of prostate can-
cer. Fourth, the function of plasma miR-410-5p is still 
unclear. It is commonly speculated that circulating miR-
NAs play key role in maintaining the homeostatic state of 
the circulatory system [33, 34]. But our research revealed 
that miR-410-5p assembling in DCs. Whether plasma 
miR-410-5p can trigger some pathogenic effects in dys-
function of DCs in PCa patients remains unclear. Finally, 
the pathogenic mechanism of miR-410-5p levels and the 
relationship with PCa is unclear. Our prior studies have 
confirmed that the release of miR-410-5p from prostate 
cancer cells may be cause of the immunologic escaping 
in PCa.
Conclusions
In conclusion, we confirmed that elevated serum miR-
410-5p level is a potential biomarker for the diagnosis of 
PCa. Our results provide a basement for future efforts 
to develop serum miR-410-5p-based assays to diagnose 
PCa.
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